David C Dale1, Audrey Anna Bolyard2, Tracy Marrero2, Merideth L Kelley1, Vahagn Makaryan1, Emily Tran2, Jamie Leung2, Laurence A Boxer3, Priya S Kishnani4, Stephanie Austin4, Corbinian Wanner5, Iris A Ferrecchia5, Dina Khalaf6, Dawn Maze6, Joanne Kurtzberg7, Cornelia Zeidler8, Karl Welte9, David A Weinstein5. 1. Division of GIM, Department of Medicine, University of Washington. 2. Department of Medicine, University of Washington, Severe Chronic Neutropenia International Registry, Seattle, Washington. 3. Pediatric Hematology Oncology, University of Michigan, Ann Arbor, Michigan. 4. Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina. 5. Department of Pediatrics, Glycogen Storage Disease Program, Connecticut Children's Medical Center, Hartford, Connecticut, USA. 6. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 7. Department of Pediatrics/Pediatric Blood and Marrow Transplantation/Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA. 8. Department of Molecular Hematopoiesis, Medizinische Hochschule Hannover, Hannover. 9. Division of Hematology/Oncology, Department of Molecular Hematopoiesis, University Children's Hospital of Tuebingen, Tuebingen, Germany.
Abstract
PURPOSE OF REVIEW: Glycogen storage disease Ib (GSD Ib) is characterized by hepatomegaly, hypoglycemia, neutropenia, enterocolitis and recurrent bacterial infections. It is attributable to mutations in G6PT1, the gene for the glucose-6-phosphate transporter responsible for transport of glucose into the endoplasmic reticulum. Neutropenia in GSD Ib is now frequently treated with granulocyte colony-stimulating factor (G-CSF). We formed a cooperative group to review outcomes of the long-term treatment of GSD Ib patients treated with G-CSF. RECENT FINDINGS: The study enrolled 103 patients (48 men and 55 women), including 47 currently adult patients. All of these patients were treated with G-CSF, starting at a median age of 3.8 years (range 0.04-33.9 years) with a median dose of 3.0 mcg/kg/day (range 0.01-93.1 mcg/kg/day) for a median of 10.3 years (range 0.01-29.3 years). Neutrophils increased in response to G-CSF in all patients (median values before G-CSF 0.2 × 10/l, on G-CSF 1.20 x 10/l). Treatment increased spleen size (before G-CSF, 47%, on treatment on G-CSF 76%), and splenomegaly was the dose-limiting adverse effect of treatment (pain and early satiety). Clinical observations and records attest to reduce frequency of infectious events and the severity of inflammatory bowel symptoms, but fever and recurrent infections remain a significant problem. In the cohort of patients followed carefully through the Severe Chronic Neutropenia International Registry, four patients have developed myelodysplasia or acute myeloid leukemia and we are aware of four other cases, (altogether seven on G-CSF, one never treated with G-CSF). Liver transplantation in five patients did not correct neutropenia. Four patients had hematopoietic stem cell transplantation; two adults and two children were transplanted; one adult and one child survived. SUMMARY: GSD Ib is a complex disorder of glucose metabolism causing severe chronic neutropenia. G-CSF is effective to raise blood neutrophil counts and reduce fevers and infections in most patients. In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.
PURPOSE OF REVIEW: Glycogen storage disease Ib (GSD Ib) is characterized by hepatomegaly, hypoglycemia, neutropenia, enterocolitis and recurrent bacterial infections. It is attributable to mutations in G6PT1, the gene for the glucose-6-phosphate transporter responsible for transport of glucose into the endoplasmic reticulum. Neutropenia in GSD Ib is now frequently treated with granulocyte colony-stimulating factor (G-CSF). We formed a cooperative group to review outcomes of the long-term treatment of GSD Ib patients treated with G-CSF. RECENT FINDINGS: The study enrolled 103 patients (48 men and 55 women), including 47 currently adult patients. All of these patients were treated with G-CSF, starting at a median age of 3.8 years (range 0.04-33.9 years) with a median dose of 3.0 mcg/kg/day (range 0.01-93.1 mcg/kg/day) for a median of 10.3 years (range 0.01-29.3 years). Neutrophils increased in response to G-CSF in all patients (median values before G-CSF 0.2 × 10/l, on G-CSF 1.20 x 10/l). Treatment increased spleen size (before G-CSF, 47%, on treatment on G-CSF 76%), and splenomegaly was the dose-limiting adverse effect of treatment (pain and early satiety). Clinical observations and records attest to reduce frequency of infectious events and the severity of inflammatory bowel symptoms, but fever and recurrent infections remain a significant problem. In the cohort of patients followed carefully through the Severe Chronic Neutropenia International Registry, four patients have developed myelodysplasia or acute myeloid leukemia and we are aware of four other cases, (altogether seven on G-CSF, one never treated with G-CSF). Liver transplantation in five patients did not correct neutropenia. Four patients had hematopoietic stem cell transplantation; two adults and two children were transplanted; one adult and one child survived. SUMMARY:GSD Ib is a complex disorder of glucose metabolism causing severe chronic neutropenia. G-CSF is effective to raise blood neutrophil counts and reduce fevers and infections in most patients. In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.
Authors: Laurence A Boxer; Audrey Anna Bolyard; Merideth L Kelley; Tracy M Marrero; Lan Phan; Jordan M Bond; Peter E Newburger; David C Dale Journal: Obstet Gynecol Date: 2015-01 Impact factor: 7.661
Authors: Jun Xia; Christopher A Miller; Jack Baty; Amrita Ramesh; Matthew R M Jotte; Robert S Fulton; Tiphanie P Vogel; Megan A Cooper; Kelly J Walkovich; Vahagn Makaryan; Audrey A Bolyard; Mary C Dinauer; David B Wilson; Adrianna Vlachos; Kasiani C Myers; Robert J Rothbaum; Alison A Bertuch; David C Dale; Akiko Shimamura; Laurence A Boxer; Daniel C Link Journal: Blood Date: 2017-11-01 Impact factor: 22.113
Authors: Vahagn Makaryan; Cornelia Zeidler; Audrey Anna Bolyard; Julia Skokowa; Elin Rodger; Merideth L Kelley; Laurence A Boxer; Mary Ann Bonilla; Peter E Newburger; Akiko Shimamura; Bin Zhu; Philip S Rosenberg; Daniel C Link; Karl Welte; David C Dale Journal: Curr Opin Hematol Date: 2015-01 Impact factor: 3.284
Authors: David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte Journal: Curr Opin Hematol Date: 2020-01 Impact factor: 3.284
Authors: Saskia B Wortmann; Johan L K Van Hove; Terry G J Derks; Nathalie Chevalier; Vijaya Knight; Andreas Koller; Esmee Oussoren; Johannes A Mayr; Francjan J van Spronsen; Florian B Lagler; Sommer Gaughan; Emile Van Schaftingen; Maria Veiga-da-Cunha Journal: Blood Date: 2020-08-27 Impact factor: 22.113
Authors: David C Dale; Audrey Anna Bolyard; James A Shannon; James A Connelly; Daniel C Link; Mary Ann Bonilla; Peter E Newburger Journal: Blood Adv Date: 2022-07-12
Authors: Dina Khalaf; Heather Bell; David Dale; Vikas Gupta; Hanna Faghfoury; Chantal F Morel; Anne Tierens; David A Weinstein; Jiong Yan; Santhosh Thyagu; Dawn Maze Journal: JIMD Rep Date: 2019-07-23
Authors: Sarah C Grünert; Roland Elling; Bärbel Maag; Saskia B Wortmann; Terry G J Derks; Luciana Hannibal; Anke Schumann; Stefanie Rosenbaum-Fabian; Ute Spiekerkoetter Journal: Orphanet J Rare Dis Date: 2020-08-24 Impact factor: 4.123